Global Radiotherapy Market Outlook
Revenue, 2024
$7.8B
Forecast, 2034
$12.8B
CAGR, 2025 - 2034
5.1%
The Radiotherapy industry revenue is expected to be around $8.2 billion in 2025 and expected to showcase growth with 5.1% CAGR between 2025 and 2034. Radiotherapy serves as a fundamental treatment method for cancer patients because health organizations focus on delivering exact treatments that preserve organs while enhancing survival rates and patient quality of life and maximizing resource efficiency. The modality has become essential for oncology treatment because hospitals and radiotherapy centers and ambulatory facilities now use it for 84.2% of their cancer treatment needs. The Systems Product segment achieved $5.79 billion in sales during 2024 because providers need advanced treatment platforms with imaging integration and workflow centric software to expand their capacity and update their equipment for outpatient care delivery.
Radiotherapy known as radiation therapy serves as a core treatment method in oncology which uses powerful radiation beams to eliminate cancer cells while protecting nearby healthy tissues through targeted delivery for various cancers including breast and lung and prostate and head and neck and central nervous system tumors and palliative care. The market evolution of external beam radiotherapy through linear accelerators and stereotactic radiosurgery platforms and image guided radiotherapy and intensity modulated radiotherapy systems and proton therapy solutions leads to better treatment accuracy and shorter treatment durations and customized cancer care which drives continuous hospital and outpatient center demand.
Market Key Insights
The Radiotherapy market is projected to grow from $7.8 billion in 2024 to $12.8 billion in 2034. This represents a CAGR of 5.1%, reflecting rising demand across Hospital Oncology, Ambulatory Radiotherapy, and Specialty Cancer Clinics.
Elekta AB, Accuray Incorporated, and Ion Beam Applications SA are among the leading players in this market, shaping its competitive landscape.
The Radiotherapy market shows its highest market share through U.S. and China as these countries will experience 3.3% to 4.9% annual growth rates from 2024 to 2030.
The market research predicts that India, Brazil and South Korea will experience the highest growth rates at 5.9% to 7.0% CAGR.
Transition like The Shift To Precision Modalities has greater influence in U.S. and China market's value chain; and is expected to add $316 million of additional value to Radiotherapy industry revenue by 2030.
.The Radiotherapy market will experience a $5.0 billion growth expansion from 2024 to 2034 while manufacturers focus on developing Internal Beam Radiotherapy/Brachytherapy Applications for market expansion.
With
rising global cancer incidence and expanding access to advanced radiotherapy infrastructure drive treatment procedure volumes, and
Integration of AI-driven treatment planning in radiotherapy enhances precision, workflow efficiency, and personalized oncology outcomes, Radiotherapy market to expand 64% between 2024 and 2034.
Opportunities in the Radiotherapy
The Asia Pacific region shows increasing demand for proton radiotherapy in pediatric brain tumor treatment at developed hospitals because it helps protect childrens cognitive function. The current radiation therapy facilities exist only in academic centers which creates a major treatment gap throughout regional healthcare networks. The market will also experience faster growth of proton beam therapy compared to conventional external beam radiotherapy because of investments in advanced radiotherapy systems and hybrid imaging and motion management technologies. Health ministries will choose vendors who provide pediatric specific treatment planning and survivorship analytics and precision oncology workflows for extended contract agreements.
Growth Opportunities in North America and Asia-Pacific
The adoption of radiotherapy in North America starts with large hospitals and integrated delivery networks but dedicated radiotherapy centers and ambulatory facilities now treat more high value patients who need stereotactic radiosurgery and image guided radiotherapy thus creating opportunities for premium system upgrades and service based contracts. The main drivers of adoption stem from solid insurance coverage for sophisticated radiation oncology methods and hospitals quick adoption of intensity modulated radiotherapy and proton therapy and their need to enhance cancer treatment results through data analytics and workflow integration software. The market competition remains fierce because established radiotherapy manufacturers must respond to competitive pricing from specialized vendors who offer AI based planning and remote monitoring and lifecycle management services. Suppliers need to combine their hardware products with software solutions and cloud analytics platforms because competitors use these bundles to outcompete them. The strategic path for growth involves two main initiatives which include hospital network and academic research institute partnerships for new linear accelerator deployment and community oncology center equipment management expansion and ambulatory radiotherapy center service delivery through flexible modular systems and advanced treatment planning tools.
The Asia Pacific region experiences growing radiotherapy needs because governments build more public hospitals and launch national cancer control initiatives which make hospitals the dominant customer base for radiotherapy services. The growing number of cancer patients and insufficient radiation oncology services and government support for local manufacturing and technology adoption create market conditions that benefit linear accelerators and adaptable brachytherapy solutions. The radiotherapy system market competition exists between international companies and local businesses which provide affordable radiotherapy equipment to hospitals that need to minimize their total ownership expenses and receive training assistance and operate within limited oncology center resources. The region needs strategic partnerships which provide upgradeable radiotherapy systems for smaller cities through flexible payment plans and long term educational and service partnerships with hospitals and research institutions to enhance clinical performance and system usage.
Market Dynamics and Supply Chain
01
Driver: Rising global cancer incidence and expanding access to advanced radiotherapy infrastructure drive treatment procedure volumes
The rising number of cancer patients because of aging populations and lifestyle risks and better screening methods leads to higher radiotherapy requirements for treating breast cancer and lung cancer and prostate cancer. The oncology teams now use radiotherapy as their first choice for treatment because they want to save organs and improve patients quality of life. The growing number of cancer patients has also led healthcare organizations to build new facilities for linear accelerators and proton therapy centers and image guided radiotherapy systems mainly in developing countries which previously lacked access to precise cancer treatment. The combination of growing cancer cases and healthcare system investments in new radiation technology platforms also drives up both treatment numbers and patient revenue worldwide. The combination of increasing medical procedures and new technology installations through public private collaborations and positive insurance coverage for IMRT and stereotactic body radiotherapy and digital platform upgrades leads to higher radiotherapy patient numbers and revenue. The worldwide radiotherapy market also experiences growth because of two main factors which include increasing patient numbers and better medical equipment availability.
Radiotherapy treatment planning has also experienced a fast paced adoption of AI which brings improvements to clinical operations and enhances treatment plan quality. Modern algorithms perform automated contouring and dose optimization and adaptive radiotherapy decision making which shortens planning duration from days to hours while enabling standardized delivery of volumetric modulated arc therapy and stereotactic radiosurgery. AI platforms that use multiple imagings and radiomics data enable personalized radiation dose delivery which matches tumor characteristics and protects sensitive organs from damage to achieve better treatment results. The new technology allows medical facilities to treat more patients while maximizing their expensive equipment and making advanced radiotherapy accessible to both large cancer centers and smaller hospitals.
02
Restraint: Escalating capital costs and reimbursement pressures restrict hospital investments in advanced radiotherapy platforms worldwide
The high initial costs of linear accelerators and proton therapy systems and imaging integrated radiotherapy equipment prevent hospitals and oncology clinics from upgrading or expanding their facilities which results in decreased installation numbers and short term revenue losses for vendors. The radiotherapy market experiences delayed growth because emerging markets lack sufficient funding for radiation therapy procedures and their reimbursement systems remain unpredictable which leads patients to choose less expensive treatment options.
03
Opportunity: Outpatient stereotactic body radiotherapy for early stage lung cancer among patients in Western Europe and Integrated radiotherapy software and services for AI driven planning in North American oncology networks
The Western European region experiences increasing numbers of early stage lung cancer cases among its aging population which demands precise outpatient stereotactic body radiotherapy treatments. Health organizations want to decrease surgical requirements and hospital expenses so they promote hypofractionated external beam radiotherapy as a suitable treatment for patients who cannot undergo surgery. The market will experience its most significant expansion through community cancer centers which provide image guided radiotherapy services with optimized outpatient cancer treatment protocols. The combination of equipment vendor partnerships with pulmonology groups and payment providers will help reveal new regional markets and speed up treatment protocol implementation.
North American oncology networks now implement integrated radiotherapy software systems with managed services to deliver standardized care throughout their multi site facilities. The radiotherapy system market will expand from 5.79 billion to 7.41 billion during 2030 while software and service segments will show higher growth from 2.01 billion to 3.11 billion with a 7.49% annual growth rate. The market demands AI based planning solutions together with adaptive radiotherapy systems and digital health platform integration capabilities. Providers who offer clinical decision support and remote contouring services with analytics based maintenance solutions can generate steady high value revenue streams.
04
Challenge: Global shortages of skilled radiation oncology professionals delay treatment access and constrain radiotherapy service capacity growth
The ongoing shortage of radiation oncology physicians and medical physicists and dosimetrists leads to treatment delays which restrict the number of radiotherapy fractions that can be performed even when equipment capacity is available. The extended wait times cause patients to choose different cancer treatments instead of radiation therapy which results in changed patient demographics and increased surgical and systemic therapy competition and reduced demand for complex radiotherapy methods.
Supply Chain Landscape
1
Radiotherapy Components
Hitachi Ltd.Ion Beam Applications SAMevion Medical Systems Inc
2
System Integration
Elekta ABAccuray IncorporatedIon Beam Applications SA
3
Software Planning
Elekta ABAccuray IncorporatedHitachi Ltd
4
Oncology End-users
HospitalsCancer treatment centersResearch institutes
1
Radiotherapy Components
Hitachi Ltd.Ion Beam Applications SAMevion Medical Systems Inc
2
System Integration
Elekta ABAccuray IncorporatedIon Beam Applications SA
3
Software Planning
Elekta ABAccuray IncorporatedHitachi Ltd
4
Oncology End-users
HospitalsCancer treatment centersResearch institutes
Use Cases of Radiotherapy in Hospital Oncology & Ambulatory
Hospital Oncology : The healthcare sector depends on hospitals to purchase radiotherapy equipment because they generate 4.88 billion dollars in annual revenue which will expand at 4.7% annually until 2024. The healthcare sector depends on external beam radiotherapy for its operations because it uses advanced intensity modulated radiotherapy and stereotactic radiosurgery to treat complex brain and head and neck and thoracic tumors through sophisticated treatment planning software and multimodality imaging systems. Hospitals achieve high patient numbers and complete oncology service delivery through their wide insurance coverage which drives demand for radiotherapy systems that make up 74.17% of total 2024 market requirements and software and service components at 25.83%. The hospital radiation department market leadership of Elekta AB and Hitachi Ltd stems from their extensive deployment of advanced systems and complete workflow solutions which generate ongoing service and software sales and control technology selection decisions.
Ambulatory Radiotherapy : The 1.69 billion dollar market from 2024 ambulatory and dedicated radiotherapy centers will expand at 5.8% CAGR because patients now receive cancer treatment as outpatients with shorter precise therapy sessions. The centers operate with external beam radiotherapy and hypofractionated protocols using compact systems that perform stereotactic radiosurgery and efficient patient handling to provide fast high dose treatments without requiring hospital admission. The main benefits of these centers include reduced expenses for equipment and maintenance and their ability to operate independently and provide radiation oncology services which generates patient referrals and enables them to implement sophisticated software solutions. The outpatient radiotherapy segment benefits from Accuray Incorporateds precision platforms and adaptive capabilities while Elekta AB and Mevion Medical Systems Inc. increase their market share through their adaptable systems and small proton therapy solutions which meet the requirements of outpatient radiotherapy facilities.
Specialty Cancer Clinics : The radiotherapy market generated 0.80 billion dollars from specialty cancer clinics during 2024 and experts predict this segment will expand at 6.7% CAGR which represents the highest growth rate among primary market segments. The clinics focus on prostate and breast cancer and pediatric tumors and other specific tumors through targeted radiation therapy methods. The medical facilities use proton therapy and brachytherapy together with advanced external beam radiotherapy to protect healthy tissues while delivering precise treatments for patients with sensitive body region's and those under 18. The clinics achieve market differentiation through their specialized cancer knowledge and patient oriented treatment approaches and advanced radiation therapy equipment which produces better results at elevated costs for particular cancers. The proton therapy system market for specialty centers depends on Ion Beam Applications SA and Mevion Medical Systems Inc. for their leading products while Accuray Incorporated advances its position through organ specific stereotactic platforms which define technology standards and market competition in this fast growing segment.
Impact of Industry Transitions on the Radiotherapy Market
As a core segment of the Medical Device industry,
the Radiotherapy market develops in line with broader industry shifts.
Over recent years, transitions such as The Shift To Precision Modalities and Convergence Of Digital And Care have redefined priorities
across the Medical Device sector,
influencing how the Radiotherapy market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
The Shift To Precision Modalities
The Radiotherapy market is undergoing a significant transformation driven by the shift towards precision modalities such as proton therapy, stereotactic radiosurgery, and image guided radiotherapy. This evolution necessitates the integration of advanced medical imaging and AI enabled treatment planning software, as equipment manufacturers innovate linear accelerators with real time imaging capabilities. Consequently, oncology centers are adapting their infrastructure, including modifications to bunkers and dosimetry labs, to support these sophisticated treatment approaches. Strategically, this transition is poised to enhance the value chain in the U.S. and China, with an anticipated addition of $321 million to the Radiotherapyindustry'srevenue by 2030, underscoring the critical importance of precision in cancer care delivery. This industry transition is expected to add $316 million in the industry revenue between 2024 and 2030.
02
Convergence Of Digital And Care
Radiotherapy has started a digital evolution because cloud based platforms now link treatment planning to patient monitoring and workflow management through automated systems. The digital transformation of radiotherapy allows doctors to perform remote contouring and virtual tumor board meetings and adaptive radiation oncology protocols which creates market needs for health IT systems and cybersecurity solutions and electronic health records with interoperability. The healthcare sector has seen growth in telemedicine services and patient engagement platforms and data analytics solutions which support value based cancer care delivery. Pharmaceutical companies use treatment data to develop combination therapies with immuno oncology and targeted drugs for patients across the world.